Evidence map›Paper›PMID 40654354›Full record

ArticleActa pharmaceutica Sinica. B2025

Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery.

Siqi Wu, Qing Tang, Weifeng Fang, Zhe Sun, Meng Zhang, Ergang Liu, Yang Cao, Yongzhuo Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Ferrum@albumin assembled nanoclusters inhibit NF-Acta pharmaceutica Sinica. B · 2025
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Siqi WuDepartment of Oncology, the First Affiliated Hospital and the First Clinical School of Guangzhou University of Chinese Medicine, Guangzhou 510000, China.
Qing TangState Key Laboratory of Traditional Chinese Medicine Syndrome, Clinical and Basic Research Team of TCM Prevention and Treatment of NSCLC, Guangdong Provincial Hospital of Chinese Medicine, the Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510000, China.
Weifeng FangSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Zhe SunDepartment of Oncology, the First Affiliated Hospital and the First Clinical School of Guangzhou University of Chinese Medicine, Guangzhou 510000, China.
Meng ZhangDepartment of Pharmacy, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Ergang LiuZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
Yang CaoDepartment of Oncology, the First Affiliated Hospital and the First Clinical School of Guangzhou University of Chinese Medicine, Guangzhou 510000, China.
Yongzhuo HuangDepartment of Oncology, the First Affiliated Hospital and the First Clinical School of Guangzhou University of Chinese Medicine, Guangzhou 510000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is aggressive, with high recurrence rates and poor prognosis. Paclitaxel (PTX) remains a key chemotherapeutic agent for TNBC, but its efficacy diminishes due to the emergence of drug resistance, largely driven by cancer stem-like cells (CSCs), vasculogenic mimicry (VM) formation and tumor immunosuppressive microenvironment (TIME). Pyruvate kinase M2 (PKM2) is highly expressed in TNBC, and is a potential target for TNBC treatment. In this study, we developed a biomimetic codelivery system using albumin nanoparticles (termed S/P NP) to co-encapsulate PTX and shikonin (SHK), a natural inhibitor of PKM2. By inhibiting PKM2, SHK suppressed

Indexed as

AlbuminCancer stem-like cellsPaclitaxelPyruvate kinase M2 (PKM2)ShikoninTriple-negative breast cancerTumor microenvironmentVasculogenic mimicry

Identifiers

PMID40654354
PMCPMC12254866

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.